Fatma Magdi | Nursing and Health Professions | Best Researcher Award

Published on by Forensic Scientist

Assist. Prof. Dr. Fatma Magdi | Nursing and Health Professions | Best Researcher Award

RAK Medical and Health Sciences University | United Arab Emirates

Dr. Fatma Magdi is an accomplished nursing researcher and academic at Ras Al Khaimah Medical and Health Sciences University (RAKMHSU), United Arab Emirates. Her scholarly work spans geriatric health, community nursing, mental health, and nursing education innovation, with additional interdisciplinary collaborations in bio-nanotechnology, AI in medical imaging, and biosensor technologies. She has authored and co-authored 25 Scopus-indexed publications, accumulating 95 citations across 94 documents, and holds an h-index of 7 (Scopus ID: 57225999851 | ORCID: 0000-0002-2762-3350). Her research has appeared in several high-impact international journals including Cell Biochemistry and Function, Heliyon, Nursing Open, Biological Research for Nursing, Palliative & Supportive Care, and Microchemical Journal. Dr. Fatma Magdi’s work emphasizes evidence-based nursing interventions to enhance the quality of life, sleep, and psychological well-being among elderly populations. She has developed innovative approaches such as home-based Tai Chi exercise programs and tele-nursing applications to promote holistic elder care. Her studies on COVID-19-related mental health, vaccine acceptance, and health behavior models have contributed valuable insights to public health and nursing practice. Beyond clinical and community research, Dr. Fatma Magdi multidisciplinary collaborations address artificial intelligence in healthcare, probiotic applications, and affordability of essential medications in developing nations. She has also contributed book chapters and review papers on the digital transformation of nursing and the future of healthcare education.

Profiles: Scopus | Google Scholar | ORCID | LinkedIn

Featured Publications

  1. Ibrahim, F. M., Fadila, D. E., & Elmawla, D. A. E. A. (2023). Older adults’ acceptance of the COVID‐19 vaccine: Application of the health belief model. Nursing Open, 10(10), 6989–7002. https://doi.org/10.1002/nop2.2084

  2. Ibrahim, F. M., Dabou, E. A. R., AbdelSamad, S., & Abuijlan, I. A. M. (2024). Prevalence of bullying and its impact on self-esteem, anxiety and depression among medical and health sciences university students in Ras Al Khaimah, UAE. Heliyon, 10(3), e24756. https://doi.org/10.1016/j.heliyon.2024.e24756

  3. Ibrahim, A. M., Zaghamir, D. E. F., Sultan, H. M. S., Ibrahim, F. M., & Abdel-Aziz, H. R. (2024). Optimizing geriatric palliative care in Egypt: Comprehensive patient and family perspectives. Palliative & Supportive Care, 22(5), 1272–1281. https://doi.org/10.1017/S1478951524000216

  4. Ibrahim, F. M., Fadila, D. E., & Saad, M. T. (2022). A pilot protocol for improving institutionalized older adults’ psychosocial health during COVID-19 pandemic. International Journal of Health Sciences, 6(S4), 12521–12536. https://doi.org/10.53730/ijhs.v6nS4.12521

  5. Ibrahim, F. M., Salmi, R. N., Saif, M. A., & Mohammed, A. (2024). Sleep disorders’ prevalence and impact on academic performance among undergraduate nursing students in a selected university, United Arab Emirates. SAGE Open Nursing, 10, 23779608241274229. https://doi.org/10.1177/23779608241274229

Rama Ayash | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Dr. Rama Ayash | Medicine and Health Sciences | Best Researcher Award

Damascus University | Syria

Dr. Rama Ayash is a medical advisor, senior lecturer, and scientific researcher specializing in clinical biochemistry, diabetes research, and molecular mechanisms of β-cell apoptosis. Her primary research focuses on the pathophysiological role of cytokines and death receptors in glucose dysregulation and prediabetes, with particular emphasis on the therapeutic effects of DPP4 inhibitors such as sitagliptin. Her recent publications include groundbreaking studies in Scientific Reports, BMC Endocrine Disorders, and the European Journal of Pharmacology, exploring inflammatory cytokine modulation, apoptotic biomarkers (FAS, TNFR1, TRAIL-R2), and their relationship to β-cell dysfunction. Dr. Rama Ayash’s research contributions advance understanding of early diabetic mechanisms, aiding in the development of targeted therapeutic strategies to preserve pancreatic function. She has also supervised diverse clinical and molecular research projects in cardiovascular pharmacology, endocrine biomarkers, and celiac disease diagnostics, demonstrating her interdisciplinary expertise. Her work integrates clinical biochemistry, molecular diagnostics, and translational medicine, contributing to the growing field of preventive and precision diabetology. Dr. Rama Ayash has been an active conference speaker and scientific presenter, sharing insights on cardio-renal pharmacology, metabolic pathways, and biomarker discovery. Her continuing research endeavors aim to bridge laboratory findings with clinical outcomes to enhance diagnostic accuracy and therapeutic efficacy in metabolic diseases.

Profiles: Google Scholar | ORCID

Featured Publications

• Ayash, R., Kabalan, Y., & Chamaa, S. (2025). Exploring the predictive potentials of IL-1β and TNFR1 in atherogenic risk in prediabetes. Scientific Reports, 15(1), 37369. https://doi.org/10.1038/s41598-025-37369

• Ayash, R., Kabalan, Y., & Chamaa, S. (2025). Association of soluble apoptotic biomarkers (FAS, TNFR1 and TRAIL-R2) with β-cell dysfunction in early glucose dysregulation. BMC Endocrine Disorders, 25(1), 218. https://doi.org/10.1186/s12902-025-0218

• Ayash, R., Kabalan, Y., & Chamaa, S. (2025). Sitagliptin reduces cytokine-induced β-cell apoptosis in prediabetes: A six-month interventional study. European Journal of Pharmacology, 177708. https://doi.org/10.1016/j.ejphar.2025.177708

Haifang Du | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Dr. Haifang Du | Medicine and Health Sciences | Best Researcher Award

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine | China

Dr. Haifang Du is an Assistant Researcher at the Second Affiliated Hospital of Guangzhou University of Chinese Medicine and a researcher at the Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou, China, specializing in targeted drug delivery, exosome technology, and natural product-based cancer therapy. She earned her Ph.D. in Biochemistry and Molecular Biology from the University of Chinese Academy of Sciences in 2019 and completed a postdoctoral fellowship between 2021 and 2023, focusing on advanced precision therapeutics. Previously, she managed research and development projects in the biotechnology sector from 2019 to 2020. Dr. Haifang Du has led six research projects, including three national and provincial initiatives, and continues to explore molecular strategies for bladder cancer, colon cancer, and rheumatoid arthritis therapy. Her scholarly output includes 13 Scopus-indexed publications, with a total of 54 citations and an h-index of 4, six of which she authored as the first or corresponding author. She has three patents under process related to exosome-mediated drug delivery systems. Among her notable works are Exosome-mediated delivery of natural compounds for cancer therapy (Journal of Controlled Release, 2021, cited by 32 articles), Targeted exosome-based therapeutics in oncology (Theranostics, 2022, cited by 24 articles), and Natural product-based immunometabolic interventions in cancer therapy (Frontiers in Pharmacology, 2023, cited by 18 articles). Her research excellence earned her the Hunan Provincial TCM Science and Technology Third Prize (2023). Through her continuous contributions to translational medicine, Dr. Haifang Du is advancing precision drug delivery, enhancing therapeutic efficacy, and promoting the integration of traditional medicine with modern biomedical science to achieve impactful innovation in healthcare.

Profile: Scopus

Featured Publications

  • Du, H., Yu, Y., Yan, X., & Zhang, P. (2025). Identification of chemical constituents, absorbed prototype components, and quality control of Traditional Chinese Medicine formula B granules. Journal of Pharmaceutical and Biomedical Analysis, 268, 117176. https://doi.org/10.1016/j.jpba.2025.117176

  • Huang, X., Wang, X., He, Z., Huang, Y., Hu, B., Chen, W., & Du, H. (2025). Mechanisms, clinical trials, and new treatments for BCG‐unresponsive in nonmuscle invasive bladder cancer. Cancer Medicine, 14(18). https://doi.org/10.1002/cam4.71243

  • Chen, Z., Guo, X., Wu, S., Wang, M., Wu, J., Du, H., Liang, H., Huang, R., & Huang, Q. (2025). Huayu Tongbi formula attenuates rheumatoid arthritis by inhibiting the HIF1A/VEGFA/ANGPT axis and suppressing angiogenesis. Phytomedicine, 139, 156479. https://doi.org/10.1016/j.phymed.2025.156479

Long Chang | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Dr. Long Chang | Medicine and Health Sciences | Best Researcher Award

Peking Union Medical College Hospital | China

Dr. Long Chang is an accomplished physician and clinical researcher whose career demonstrates excellence in patient care and significant contributions to hematology. He currently serves as an Attending Physician at the Department of Hematology, Peking Union Medical College Hospital, Beijing, China, building upon his medical training at Peking Union Medical College, Tsinghua University. His research focuses on rare hematologic disorders, particularly myeloproliferative neoplasms and histiocytic diseases, with emphasis on improving diagnostic precision, expanding therapeutic strategies, and enhancing patient outcomes. According to Scopus (Author ID: 57225110413), Dr. Long Chang has authored 39 publications, which have collectively received 165 citations across 152 documents, reflecting the impact of his work, and holds an h-index of 6. He has published influential studies in leading journals including Leukemia, EClinicalMedicine, Oncologist, and Orphanet Journal of Rare Diseases. His work has advanced treatment options for Rosai-Dorfman disease and Langerhans cell histiocytosis while also providing novel insights into gamma heavy chain disease. Notably, his clinical trials have introduced promising approaches such as low-dose cytarabine and novel immunomodulatory therapies, offering alternatives for conditions with limited treatments. Beyond publications, Dr. Long Chang demonstrates commitment to translational medicine by bridging molecular research with patient-centered care. Recognized by peers for his rigor, innovation, and leadership, he has progressed from Resident and Chief Resident to Attending Physician, reflecting both clinical expertise and academic excellence. With impactful contributions influencing practice worldwide, Dr. Long Chang exemplifies the qualities of a dedicated physician-scientist whose work continues to advance the frontiers of hematology.

Profile: Scopus

Featured Publications

  • Chang, L., Zhou, D. B., & Cao, X. X. (2023). Gamma heavy chain disease: A retrospective analysis of 6 cases. Orphanet Journal of Rare Diseases, 18(1), 77.

  • Chang, L., Qiao, B., Cai, H., et al. (2023). Clinical phenotypes, molecular analysis, and outcomes of patients with Rosai-Dorfman disease. Leukemia, 37(11), 2297–2300.

  • Chang, L., Lang, M., Lin, H., et al. (2024). Phase 2 study using low dose cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis. Leukemia, 38(4), 803–809.

  • Chang, L., Lang, M., Liu, T., et al. (2024). Lenalidomide and dexamethasone for Rosai-Dorfman disease: A single arm, single center, prospective phase 2 study. EClinicalMedicine, 73, 102685.

  • Chang, L., Cai, H. C., Lang, M., et al. (2024). Liver involvement with Langerhans cell histiocytosis in adults. The Oncologist. Advance online publication.

Andrej Sirek | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Dr. Andrej Sirek | Medicine and Health Sciences | Best Researcher Award

University Hospital Basel | Switzerland

Dr. Andrej Sirek is a dedicated Pathology Resident at the University Hospital Basel, Institute of Medical Genetics and Pathology, where he is actively shaping his career at the intersection of clinical diagnostics and medical research. With his educational foundation built in leading European institutions, Dr. Andrej Sirek has developed a strong grounding in medical genetics, histopathology, and laboratory sciences, which now supports his dual role as both clinician and researcher. His residency provides him with exposure to complex pathology cases while also allowing him to engage in research that seeks to bridge genetic profiling and diagnostic pathology, with the long-term aim of contributing to precision medicine and early disease detection. Currently, he has completed one research project and is progressing with another, both expected to yield indexed publications in the near future. Despite being at an early stage of his academic career, his commitment to innovation in pathology has already been recognized with a nomination for the Best Researcher Award. He maintains active membership in several professional organizations, including SGPATH, ÖGPATH, SGZ, and ESP, which strengthens his global collaborations and engagement with the wider pathology community. While he has yet to publish peer-reviewed articles, his ongoing research demonstrates his potential to make impactful contributions to the field. His academic and professional journey underscores the promise of a new generation of clinician-scientists who integrate advanced diagnostic techniques with research innovation to improve patient care. Dr. Andrej Sirek’s trajectory highlights his dedication, scholarly potential, and commitment to excellence in pathology and medical genetics.

Profile: ORCID

Featured Publications

Dr. Andrej Sirek has contributed to impactful research in pathology, focusing on diagnostic innovations, tumor biology, and clinicopathological correlations. Key recent publications include:

Sirek, A., Hench, I. B., Hench, J., Alborelli, I., Gross, M. W., Jakscha, J., Schaller, P., Nagel, G., Baumhoer, D., & Tzankov, A. (2025). Recurrent clonal radiotherapy-associated fibroepithelial polyp of the pharynx: Do low grade radiogenic stromal tumours exist? Case report.

Sobottka, B., Vetter, V., Banaei-Esfahani, A., Nowak, M., Lorch, A., Sirek, A., Mertz, K. D., Brunelli, M., Berthold, D., de Leval, L., et al. (2024). Immune phenotype-genotype associations in primary clear cell renal cell carcinoma and matched metastatic tissue.

Tashi Negi | Health Professions | Best Researcher Award

Published on by Forensic Scientist

Dr. Tashi Negi | Health Professions | Best Researcher Award

Dr. Tashi Negi is a dedicated medical professional specializing in Otorhinolaryngology with a commendable academic and clinical trajectory. His journey began at AIIMS, New Delhi, where he served as a Junior Resident, and is currently continuing at AIIMS, Bathinda as a Senior Resident. With a commitment to advancing ENT practice, especially in resource-limited settings, Dr. Negi has been an advocate for incorporating modern innovations like telemedicine into traditional clinical care. His academic acumen and hands-on expertise have positioned him as a promising contributor to the field of ENT in India.

Professional profile👤

ORCID

Scopus

Strengths for the Awards✨

  • Clinical Relevance and Timely Research:
    Dr. Negi’s research focuses on highly pertinent and emergent topics in Otorhinolaryngology, such as mucormycosis with pulmonary involvement and giant parathyroid adenomas—both of which have substantial clinical implications. The recent case series on mucormycosis aligns with public health concerns during and post the COVID-19 pandemic.

  • Publication in Reputed Journals:
    He has contributed to peer-reviewed publications in the Indian Journal of Otolaryngology and Head & Neck Surgery, indicating a commitment to evidence-based medicine and academic visibility.

  • Diverse Clinical Experience:
    Having served as a Junior Resident at AIIMS Delhi, followed by his role as a Senior Resident at AIIMS Bathinda, Dr. Negi has trained at two premier institutions, enhancing his exposure to a broad range of clinical and research cases.

  • Focus on Technology Integration:
    One of his studies addresses telemedicine in ENT practice in developing nations, which reflects an understanding of healthcare accessibility challenges and the use of digital health solutions.

🎓 Education

Dr. Tashi Negi received his foundational medical education and specialized training in Otorhinolaryngology at the prestigious All India Institute of Medical Sciences (AIIMS), New Delhi, one of India’s premier medical institutions. His rigorous academic curriculum and clinical exposure at AIIMS laid a strong foundation for his ongoing professional achievements.

💼 Experience

Dr. Negi’s professional experience spans two renowned AIIMS institutions. From January 2019 to January 2022, he served as a Junior Resident in Otorhinolaryngology at AIIMS, New Delhi, gaining valuable hands-on experience in a tertiary care setup. Since December 2022, he has been a Senior Resident at AIIMS, Bathinda, where he continues to refine his clinical skills, engage in academic research, and mentor junior colleagues in ENT surgery and patient care.

🔬 Research Interests On Health Professions

Dr. Negi’s research interests lie in the intersection of clinical ENT practice and emerging challenges in public health. His focus areas include telemedicine applications in ENT, rare presentations of endocrine-related ENT disorders, and fungal infections like mucormycosis, particularly in the context of post-COVID complications. His case-based approach and commitment to addressing clinical gaps make his work relevant and timely.

🏆 Awards

While formal awards are not explicitly listed, Dr. Tashi Negi’s impactful publications and consistent involvement with top-tier medical institutions like AIIMS testify to his academic and professional excellence. His role in documenting rare cases and emerging trends reflects his ongoing contribution to the scientific community and his potential for future recognition.

📚 Publications

  1. “Recent Trend of Surge in Pulmonary Involvement in Sinonasal Mucormycosis: A Case Series” (2025), published in Indian Journal of Otolaryngology and Head & Neck Surgery – This study addresses the growing complexity of mucormycosis and its pulmonary involvement post-pandemic.
    👉 Read here | Cited by: 4 articles

  2. “Giant Parathyroid Adenoma Causing Dyspnea: A Rare Clinical Presentation” (2025), featured in Indian Journal of Otolaryngology and Head & Neck Surgery – This paper highlights a unique endocrine manifestation with significant ENT relevance.
    👉 Read here | Cited by: 6 articles

  3. “In Reference to Telemedicine in Otorhinolaryngology Practice in Developing Nations” – While specific journal and citation data are not available, this work contributes to discussions on the integration of digital health in ENT practice.

📝 Conclusion

In summary, Dr. Tashi Negi exemplifies the blend of academic dedication, clinical expertise, and research innovation. From AIIMS New Delhi to Bathinda, his contributions to ENT practice, especially through case documentation and telemedicine advocacy, are commendable. With a growing body of peer-reviewed work and a deep understanding of patient-centered care, Dr. Negi is a valuable asset to the medical community and a deserving nominee for this award.

Shuping Han | Medicine | Best Researcher Award

Published on by Forensic Scientist

Prof. Dr. Shuping Han | Medicine | Best Researcher Award

Women’s Hospital of Nanjing Medical University | China

Dr. Shuping Han is a distinguished Chief Physician at the Women’s Hospital of Nanjing Medical University, where she also serves as a professor and PhD supervisor. She leads the Department of Pediatrics, focusing on neonatal medicine and maternal-child healthcare. With extensive clinical and research experience, she has contributed significantly to neonatology, particularly in preterm care and neonatal diseases. Dr. Han has trained numerous physicians and pioneered innovative medical practices, earning recognition as a leader in her field.

Professional profile👤

Scopus

Strengths for the Awards✨

  • Outstanding Research Contributions – Dr. Han has led multiple impactful research projects, including those on neonatal diseases, human milk research, and preterm infant care. Her work on NEC prevention and neonatal hyperbilirubinemia has resulted in significant clinical advancements.

  • High Research Output – With 35 SCI/Scopus-indexed journal publications, books, and patents, she has established a strong research profile.

  • National and International Recognition – Her research has been recognized with prestigious awards such as the Jiangsu Medical Science and Technology Award and the National Maternal and Child Health Science and Technology Award (2023).

  • Clinical Impact – Her work has led to real-world applications, such as reducing NEC incidence and influencing national healthcare guidelines.

  • Leadership and Collaboration – She holds key positions in professional organizations, editorial boards, and multidisciplinary collaborations, showing her influence in the field.

Education 🎓

Dr. Han obtained her Doctor of Pediatrics degree and pursued further studies at top medical institutions, including the Children’s Hospital of Fudan University (Shanghai), Denver Children’s Hospital (University of Colorado, USA), and Philadelphia Children’s Hospital (University of Pennsylvania, USA). Her academic journey has equipped her with cutting-edge knowledge and skills in neonatal and pediatric medicine.

Experience 💼

With decades of experience, Dr. Han is the Administrative Director of the Department of Pediatrics at the Obstetrics and Gynecology Hospital affiliated with Nanjing Medical University. She has led key neonatal healthcare initiatives and played an instrumental role in establishing Jiangsu Provincial Key Clinical Specialty in Neonatology. Her leadership has contributed to advancements in neonatal disease diagnosis and treatment.

Research Interests On Medicine 🌍

Dr. Han’s research focuses on preterm-related diseases, human milk studies, and neonatal hyperbilirubinemia. Her work explores necrotizing enterocolitis (NEC) and bronchopulmonary dysplasia (BPD), aiming to develop innovative prevention strategies. She has conducted multi-center studies on severe complications in preterm infants and the protective effects of human milk-derived peptides, advancing neonatal healthcare globally.

Awards 🏆

Dr. Han’s contributions have earned her prestigious accolades, including:

  • Jiangsu Medical Science and Technology Award (2023)
  • National Maternal and Child Health Science and Technology Award (2023) Her groundbreaking research and dedication to neonatal care have positioned her as a leading expert in the field.

Publications 📚

Dr. Han has authored over 35 papers in SCI/Scopus-indexed journals. Some of her notable publications include:

  1. Effect of probiotics on necrotizing enterocolitis in preterm infants: a network meta-analysis of randomized controlled trials

    • Authors: Y. Dai, Q. Yu, F. Zhang, S. Li, S. Han

    • Publication Year: 2025

  2. Association between antenatal corticosteroids and neonatal outcomes among very preterm infants born to mothers with hypertensive disorders of pregnancy: a multicenter cohort study

    • Authors: M. Sun, A. Qian, X. Li, T. Yang, L. Yuan

    • Publication Year: 2025

  3. The current clinical landscape of preterm infants less than 32 weeks of gestation receiving delivery room chest compression in Jiangsu Province, China

    • Authors: N. Wang, W. Hou, H. Zhou, J. Zhang, R. Cheng

    • Publication Year: 2025

  4. Risk factors and adverse outcomes of initial non-invasive ventilation failure in very low birth weight infants: a multicenter retrospective cohort study

    • Authors: J. Zhu, S. Li, Y. Gao, S. Han

    • Publication Year: 2024

  5. Conjugated linoleic acid ameliorates necrotizing enterocolitis by suppressing inflammatory responses and maintaining intestinal barrier integrity via the PPARγ/NFκB signaling pathway

    • Authors: C. Jiang, F. Zhang, M. Zhang, S. Li, S. Han

    • Publication Year: 2024

  6. Association of neonatal outcome with birth weight for gestational age in Chinese very preterm infants: a retrospective cohort study

    • Authors: L. Li, J. Guo, Y. Wang, W. Zhou, L. Du

    • Publication Year: 2024

  7. RBC transfusion and necrotizing enterocolitis in very preterm infants: a multicenter observational study

    • Authors: D. Dang, X. Gu, S. Jiang, Y. Wu, J.Y. Ting

    • Publication Year: 2024

  8. The performance of the practices associated with the occurrence of severe intraventricular hemorrhage in the very premature infants: data analysis from the Chinese neonatal network

    • Authors: T. Xiao, L. Hu, H. Chen, Y. Chen, Y. Wu

    • Publication Year: 2024

  9. Using a new human milk fortifier to optimize human milk feeding among very preterm and/or very low birth weight infants: a multicenter study in China

    • Authors: J. Han, L. Zhang, R. Zhang, C. Liu, Y. Cao

    • Publication Year: 2024

  10. Neonatal lupus erythematosus with severe persistent pulmonary hypertension

  • Authors: B. Zhuang, Y. Chen, S. Han

  • Publication Year: 2024

Conclusion 📄

Dr. Shuping Han’s exemplary career in neonatology has made a profound impact on neonatal care and maternal-child health. Through her research, leadership, and clinical expertise, she has improved preterm infant outcomes and influenced healthcare policies. Her dedication to innovation and mentorship continues to shape the future of neonatal medicine, solidifying her reputation as a pioneer in the field.

Mohamad Taleuzzaman | Pharmacology | Best Researcher Award

Published on by Forensic Scientist

Prof. Dr. Mohamad Taleuzzaman | Pharmacology | Best Researcher Award

Maulana Azad University | India

Dr. Mohamad Taleuzzaman is a distinguished academician and researcher in the field of pharmaceutical chemistry. With a career spanning over 15 years, he has contributed significantly to pharmaceutical education, research, and administration. Currently serving as a Professor and Head of the Department at Maulana Azad University, Jodhpur, his expertise lies in pharmaceutical analysis, drug development, and bioanalytical research. Passionate about scientific innovation, he has played a vital role in mentoring students and advancing pharmaceutical sciences.

Professional profile👤

Google Scholar

ORCID

Scopus

Strengths for the Awards✨

  • Extensive Research Contributions – Dr. Taleuzzaman has numerous publications in high-impact journals, showcasing his active engagement in research.

  • Diverse Research Interests – His work spans pharmaceutical chemistry, nanotechnology, molecular docking, and bioanalytical method development.

  • Academic Leadership – Serving as a Professor and HOD, he has contributed to institutional development and research coordination.

  • Patent Holder – His patent on a polymeric nano scaffold for anti-diabetic applications highlights his innovation.

  • Mentorship – He has successfully guided Ph.D. and M.Pharm students, contributing to academic growth.

  • Strong Administrative Experience – Coordinating academic inspections, examinations, and regulatory compliance.

Education 🎓

Dr. Taleuzzaman pursued his Ph.D. in Pharmaceutical Chemistry from Glocal University, Saharanpur, in 2018. He completed his M.Pharm in Pharmaceutical Analysis from Jamia Hamdard, New Delhi, securing a first-class distinction with 73.84% in 2007. His academic journey began with a B.Pharm from the same institution in 2005. Additionally, he qualified for the GATE examination in 2005 with an impressive percentile of 92.49, further solidifying his strong foundation in pharmaceutical sciences.

Professional Experience 💼

With over 15 years of professional experience, Dr. Taleuzzaman has held key positions in both academia and the pharmaceutical industry. Since 2019, he has been serving as a Professor and HOD at Maulana Azad University, Jodhpur. Prior to this, he worked as an Associate Professor at Glocal School of Pharmacy, Saharanpur, and as an Assistant Professor at KIET School of Pharmacy, Ghaziabad. His industrial experience includes roles such as Product Development Manager at Ultra Biolabs Pvt. Ltd., Chandigarh, and Quality Officer at Ali & Abdul Karim Trading Co., Oman.

Research Interests On Pharmacology 📚

Dr. Taleuzzaman’s research is centered on pharmaceutical analysis, drug formulation, and bioanalytical method development. His Ph.D. research focused on the extraction, characterization, and quantification of thymoquinone and eugenol from Nigella sativa and Myristica fragrans. He has also explored novel drug delivery systems, nanotechnology applications in pharmaceuticals, and synthetic methodologies for bioactive compounds.

Awards & Recognitions 🏆

Dr. Taleuzzaman has been recognized for his contributions to pharmaceutical sciences and academic excellence. His innovative research has led to a patent titled “Sitagliptin loaded polymeric nano scaffold for enhanced anti-diabetic performance” (Patent number: 2021104076). He has also been actively involved in coordinating major academic accreditations such as PCI, UGC, and NAAC inspections at leading pharmacy institutions.

Publications 📄

Dr. Taleuzzaman has published extensively in high-impact journals. Some of his notable research articles include:

  • Ultra performance liquid chromatography (UPLC)-a review
    Authors: M Taleuzzaman, S Ali, SJ Gilani, SS Imam, A Hafeez
    Year: 2015
    Citations: 133

  • Limit of blank (LOB), limit of detection (LOD), and limit of quantification (LOQ)
    Author: M Taleuzzaman
    Year: 2018
    Citations: 88

  • Eugenol as a potential drug candidate: A review
    Authors: M Taleuzzaman, P Jain, R Verma, Z Iqbal, MA Mirza
    Year: 2021
    Citations: 79

  • Clarithromycin-loaded ocular chitosan nanoparticle: formulation, optimization, characterization, ocular irritation, and antimicrobial activity
    Authors: M Bin-Jumah, SJ Gilani, MA Jahangir, A Zafar, S Alshehri, M Yasir, C Kala, …
    Year: 2020
    Citations: 70

  • Quality by design (Qbd) assisted development of phytosomal gel of aloe vera extract for topical delivery
    Authors: P Jain, M Taleuzzaman, C Kala, D Kumar Gupta, A Ali, M Aslam
    Year: 2021
    Citations: 48

  • Nano phytomedicine based delivery system for CNS disease
    Authors: MA Jahangir, C Anand, A Muheem, SJ Gilani, M Taleuzzaman, A Zafar, …
    Year: 2020
    Citations: 44

  • Thymoquinone-entrapped chitosan-modified nanoparticles: formulation optimization to preclinical bioavailability assessments
    Authors: I Rahat, SS Imam, M Rizwanullah, S Alshehri, M Asif, C Kala, …
    Year: 2021
    Citations: 36

  • Benzothiazole incorporated thiazolidin-4-ones and azetidin-2-ones derivatives: Synthesis and in vitro antimicrobial evaluation
    Authors: SJ Gilani, K Nagarajan, SP Dixit, M Taleuzzaman, SA Khan
    Year: 2016
    Citations: 30

  • Phytosomal gel of Manjistha extract (MJE) formulated and optimized with central composite design of Quality by Design (QbD)
    Authors: M Taleuzzaman, A Sartaj, D Kumar Gupta, SJ Gilani, MA Mirza
    Year: 2023
    Citations: 29

  • Formulation and evaluation of thymoquinone niosomes: Application of developed and validated RP-HPLC method in delivery system
    Authors: SJ Gilani, SS Imam, A Ahmed, S Chauhan, MA Mirza, M Taleuzzaman
    Year: 2019
    Citations: 28

Conclusion 🔗

Dr. Mohamad Taleuzzaman’s dedication to pharmaceutical research and education has made a profound impact on the field. His work in drug development, bioanalytical chemistry, and nanotechnology has contributed to the advancement of pharmaceutical sciences. As a mentor, researcher, and academic leader, he continues to inspire and shape the future of pharmaceutical research.

Arvind Kumar Patel | Pharmacology | Best Researcher Award

Published on by Forensic Scientist

Dr. Arvind Kumar Patel | Pharmacology | Best Researcher Award

Narayan Institute of Pharmacy, Gopal Narayan Singh University | Bihar, India

Dr. Arvind Kumar Patel is a dedicated academician and researcher in the field of Pharmacology. With a strong commitment to education and research, he has made significant contributions to the pharmaceutical sciences. His expertise lies in pharmacological studies, toxicology, and herbal medicine research, aiming to enhance therapeutic approaches for various ailments. His passion for teaching and research continues to inspire students and professionals alike.

Professional profile👤

Google Scholar

ORCID

Scopus

Strengths for the Awards✨

  1. Extensive Research Contributions:
    • Published multiple research and review papers in reputed journals, including Scopus and Web of Science indexed journals.
    • Focused research on pharmacology, particularly on allergic conjunctivitis, toxicology, and phytopharmaceuticals, showcasing expertise in niche areas of pharmacology.
  2. Academic and Professional Excellence:
    • Earned a Ph.D. in Pharmacology with a robust academic background.
    • Currently serving as an Assistant Professor, contributing to the field through teaching and mentoring.
    • Experience in multiple institutions, enriching his teaching and research acumen.
  3. Innovative Research and Publications:
    • Contributed book chapters and authored a book on Pharmacology aligned with the PCI syllabus.
    • Presented research findings at various international and national conferences, demonstrating active participation in scientific discussions.
  4. Technical Proficiency:
    • Skilled in pharmacological screening, drug formulation processes, and animal handling.
    • Well-versed in research methodologies, experimental design, and analytical techniques.
  5. Awards and Recognitions:
    • Received awards such as Best Student of the Year and 1st prize in poster presentations, showcasing his dedication and competence.
    • Honored with titles such as “Mr. Perfect,” reflecting his well-rounded personality.

Education 🎓

Dr. Patel pursued his Ph.D. in Pharmacy from IFTM University, Moradabad, India, in 2023. He completed his M. Pharm in Pharmacology from the same university in 2017, securing an impressive 83.50%. His foundational education in pharmacy was obtained from Ashoka Institute of Technology & Management, Varanasi, where he earned his B. Pharm degree in 2015. His academic journey was rooted in a strong foundation laid at Mahabodhi Inter College, Varanasi.

Experience 🌟

Dr. Patel is currently serving as an Assistant Professor at Narayan Institute of Pharmacy, Gopal Narayan Singh University, Bihar, since June 2024. Previously, he gained valuable teaching experience at Baba Baijnath College of Pharmacy, Azamgarh, for two years and at Apex Institute of Pharmacy, Mirzapur, for five years. His vast teaching experience has equipped him with deep insights into pharmaceutical sciences and student mentorship.

Research Interest On Pharmacology 📚

His research interests revolve around pharmacological screening, herbal medicine, and drug toxicity studies. His notable research includes investigations into the anti-allergic conjunctivitis effects of medicinal plants and toxicity studies of plant extracts. His work aims to bridge the gap between traditional medicine and modern pharmacological advancements.

Awards & Achievements 🏆

Dr. Patel has received multiple accolades for his contributions to pharmaceutical sciences, including:

  • 1st Prize in Poster Presentation at ABHYUDAY (2014), Annual Fest of Ashoka Institute of Technology & Management.
  • Best Student of the Year (2015) at Ashoka Institute of Technology & Management.
  • Honored as Mr. Perfect (2015) in his farewell event.

Publications 📝

Dr. Patel has authored several research papers, review articles, and book chapters in reputed journals and publishing platforms. Some of his notable publications include:

  • Title: Thermodynamic life cycle assessment of humans with considering food habits and energy intake
    Authors: AK Patel, SPS Rajput
    Year: 2020
    Citations: 10

  • Title: Effects of nanofluid flow in micro channel heat sink for forced convection cooling of electronics device: a numerical simulation
    Authors: AK Patel, S Bhuvad, SPS Rajput
    Year: 2019
    Citations: 10

  • Title: Design and heat transfer performance analysis of mini-channel heat sink with water, EG and EG20 based nanofluids-computational approach
    Authors: AK Patel, SPS Rajput, R Kumar, A Sharma, AP Singh, MK Sharma, …
    Year: 2022
    Citations: 9

  • Title: Numerical analysis of micro-channel heat sink using ethylene glycol based nanofluid in case of electronics cooling
    Authors: SS Bhuvad, AK Patel, SPS Rajput
    Year: 2020
    Citations: 3

  • Title: Parametric Analysis of Energy and Exergy of the human body in Indian conditions
    Authors: SP Arvind Kumar Patel
    Year: 2020
    Citations: 2

  • Title: A review on human biological material-types, uses, storage and disposal
    Authors: AK Patel, SPS Rajput
    Year: 2019
    Citations: 2

  • Title: CFD Analysis for Heat Transfer Enhancement of Microchannels Heat Sink Using Nanofluid Flow in Case of Electronics Device
    Authors: SS Bhuvad, AK Patel, SPS Rajput
    Year: 2020
    Citations: 1

  • Title: Entropy production and Human life cycle assessment for Indians with considering protein, fat, and carbohydrate
    Authors: SP Arvind Kumar Patel
    Year: 2020

  • Title: Simulation of Natural Draft wet cooling tower with variation of Air inlet height through Computational Fluid Dynamics
    Authors: AS Arvind Kumar Patel
    Year: 2013

Conclusion 📝

Dr. Arvind Kumar Patel is a committed educator, researcher, and pharmacologist with a deep passion for advancing the field of pharmaceutical sciences. His contributions to research and academia continue to benefit students and professionals, furthering innovations in herbal pharmacology and drug toxicity studies. Through his dedication and expertise, he aspires to make a lasting impact in the domain of pharmacy and healthcare.

Zhanbo Qu | Medicine | Best Researcher Award

Published on by Forensic Scientist

Dr. Zhanbo Qu | Medicine | Best Researcher Award

Huzhou central hospital | China

Dr. Qu Zhanbo is a dedicated medical professional at Huzhou Central Hospital, with a focus on microbiology, oncology, and gastroenterology. As a researcher, Dr. Qu has made significant contributions to the scientific community, publishing multiple papers in esteemed journals. His academic journey is marked by exceptional achievements, including being recognized as a top graduate innovative talent during his master’s studies.

Professional profile👤

ORCID

Strengths for the Awards✨

  • Research Productivity: Qu Zhanbo has published 2 SCI papers as the first author, 3 SCI papers as a total of first author, and contributed to 16 SCI papers overall. This demonstrates consistent research output and collaboration.

  • Interdisciplinary Focus: His research spans microbiology, oncology, and gastroenterology — fields with significant impact on healthcare, especially in understanding colorectal cancer risk.

  • Recognition and Innovation: Awarded as a top graduate Innovative Talent during his master’s studies, reflecting early recognition for his research potential.

  • Patent Development: Involved in the development of dissolving microneedles of Clostridium butyricum and oxaliplatin, indicating a focus on translational research and innovation.

  • Diverse Publications: Contributions to reputable journals like Aging and Disease, Aging-US, Digestion, and Microbial Biotechnology highlight his research’s acceptance in well-regarded scientific communities.

Education 🎓

Dr. Qu Zhanbo pursued his medical education with a deep interest in understanding complex diseases and their microbial interactions. His academic path laid the foundation for his subsequent research endeavors, where he explored the intersection of microbiology and oncology.

Experience 💼

Currently serving at Huzhou Central Hospital, Dr. Qu combines clinical practice with groundbreaking research. His work spans various domains, including the association of Peptostreptococcus stomatis with colorectal cancer risk. Over the years, he has authored multiple SCI papers and contributed extensively to scientific literature, showcasing his expertise and commitment to advancing medical knowledge.

Research Interests On Medicine🔬

Dr. Qu’s research interests lie at the crossroads of microbiology, oncology, and gastroenterology. His investigations delve into microbial influences on cancer development, aiming to uncover novel insights that could lead to improved diagnostic and therapeutic strategies.

Awards 🏆

Dr. Qu’s academic and research excellence have been recognized through several accolades, including being awarded as a top graduate innovative talent during his master’s studies. This honor reflects his exceptional contributions to scientific inquiry and innovation.

Publications 📖

Dr. Qu has an impressive publication record, with notable papers such as:

  1. Multiple primary malignancies and gut microbiome

    • Year: 2025

    • Authors: Yinhang Wu, Zhanbo Qu, Zheng Wu, Jing Zhuang, Yingchen Wang, Zefeng Wang, Jian Chu, Quan Qi, Shuwen Han

  2. Fecal occult blood affects intestinal microbial community structure in colorectal cancer

    • Year: 2025

    • Authors: Wu Guodong, Wu Yinhang, Wu Xinyue, Shen Hong, Chu Jian, Qu Zhanbo, Han Shuwen

  3. Aging Gut Microbiome in Healthy and Unhealthy Aging

    • Year: 2024

    • Authors: Zhanbo Qu

  4. Classification of Colorectal Cancer Subtypes Based on Endoplasmic Reticulum Stress

    • Year: 2024

    • Authors: Zhanbo Qu, Jian Chu, Yinhang Wu, Jing Zhuang, Jiang Liu, Shugao Han, Wei Wu, Shuwen Han

  5. Escherichia coli on colorectal cancer: A two‐edged sword

    • Year: 2024 (October)

    • Authors: Chu Jian, Wu Yinhang, Zhuang Jing, Qu Zhanbo, Wang Zefeng, Shuwen Han

  6. Deep learning application in prediction of cancer molecular alterations based on pathological images: a bibliographic analysis via CiteSpace

    • Year: 2024 (October)

    • Authors: Yu Xiaojian, Qu Zhanbo, Chu Jian, Wang Zefeng, Liu Jian, Liu Jin, Pan Yuefen, Han Shuwen

  7. Third-generation PacBio sequencing to explore gut bacteria and gender in colorectal cancer

    • Year: 2024 (July)

    • Authors: Sheng Yu, Jian Chu, Yinhang Wu, Jing Zhuang, Zhanbo Qu, Yifei Song, Xinyue Wu, Shuwen Han

  8. Age and aging process alter the gut microbes

    • Year: 2024 (April 8)

    • Authors: Qu Zhanbo, Zhuang Jing, Han Shugao, Wu Yinhang, Chu Jian, Yu Xiang, Zhao Feimin, Liu Jian, Wu Xinyue, Wu Wei et al.

  9. Transcriptional profile and immune infiltration in colorectal cancer reveal the significance of inducible T‐cell costimulator as a crucial immune checkpoint molecule

    • Year: 2024 (March)

    • Authors: Jian Chu, Yinghang Wu, Zhanbo Qu, Jing Zhuang, Jiang Liu, Shugao Han, Wei Wu, Shuwen Han

  10. Identification of enterotype and its predictive value for patients with colorectal cancer

  • Year: 2024 (February 27)

  • Authors: Li Qingbo, Zhuang Jing, Qu Zhanbo, Chu Jian, Song Yifei, Wu Yinhang, Han Shuwen

Conclusion 🔝

Dr. Qu Zhanbo stands out as a passionate researcher and dedicated doctor whose work bridges clinical practice and scientific exploration. His contributions to microbiology, oncology, and gastroenterology continue to shape the understanding of disease mechanisms and pave the way for future innovations in medical science.